Fresenius Medical Care AG (NYSE:FMS) Shares Purchased by Franklin Resources Inc.

Franklin Resources Inc. raised its position in Fresenius Medical Care AG (NYSE:FMS) by 3.3% during the third quarter, HoldingsChannel reports. The firm owned 74,640 shares of the company’s stock after purchasing an additional 2,386 shares during the period. Franklin Resources Inc.’s holdings in Fresenius Medical Care were worth $1,490,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in FMS. Wulff Hansen & CO. grew its position in shares of Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares in the last quarter. Moran Wealth Management LLC grew its holdings in shares of Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after purchasing an additional 74,621 shares during the period. Quantinno Capital Management LP grew its holdings in shares of Fresenius Medical Care by 78.9% in the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after purchasing an additional 48,554 shares during the period. Triasima Portfolio Management inc. increased its position in Fresenius Medical Care by 27.4% during the second quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock worth $1,631,000 after purchasing an additional 18,360 shares during the last quarter. Finally, Crossmark Global Holdings Inc. raised its stake in Fresenius Medical Care by 60.4% during the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock worth $1,340,000 after purchasing an additional 23,692 shares during the period. Institutional investors and hedge funds own 8.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on FMS. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. StockNews.com started coverage on Fresenius Medical Care in a research report on Thursday, November 28th. They set a “strong-buy” rating for the company. Truist Financial upped their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $24.30.

Fresenius Medical Care Stock Up 0.4 %

Shares of NYSE:FMS opened at $22.97 on Friday. The firm’s 50-day moving average is $22.09 and its two-hundred day moving average is $20.59. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care AG has a 1 year low of $17.93 and a 1 year high of $24.31. The firm has a market capitalization of $13.48 billion, a PE ratio of 18.98, a price-to-earnings-growth ratio of 0.96 and a beta of 0.94.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.